icon
موقع حكومي رسمي تابع لحكومة المملكة العربية السعودية
icon الخميس 10 محرم 1448هـ
نسخة تجريبية
icon
روابط المواقع الالكترونية الرسمية السعودية تنتهي بـ gov.sa

جميع روابط المواقع الرسمية التابعة للجهات الحكومية في المملكة العربية السعودية تنتهي بـ .gov.sa

icon
المواقع الالكترونية الحكومية تستخدم بروتوكول HTTPS للتشفير والأمان.

جميع روابط المواقع الرسمية التابعة للجهات الحكومية في المملكة العربية السعودية تنتهي بـ .gov.sa

icon
مسجل لدى هيئة الحكومة الرقمية برقم :
20250831619
اقتراحات

قائمة الدراسات السريرية المسجلة على الادوية

عرض 51 - 60 من 485
عنوان الدراسة داعم الدراسة حالة الدراسة دواء الدراسة مرحلة الدراسة رقم بروتوكول الدراسة موقع الدراسة
A multicenter real-world evidence study with retrospective chart review and cross-sectional survey to evaluate the satisfaction and benefits of long-term repeated BOTOX treatment for upper facial lines AbbVie Ongoing Botox 4 H24-500 Derma Clinic
Phase II, Prospective, Randomized, placebo-controlled, double-blind study.Evaluation of Phytochemical properties and Phytotherapeutic Potential of Boswellia carteri Birdw. in Psoriasis PI Initiated Ongoing boswellia carteri (Psorelia) 2 E-23-7585 King Khalid University Hospital (Riyadh)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Inhalation of Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH) Gossamer Bio Ongoing Seralutinib 3 GB002-3101 King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Medical City (Riyadh)
Long-term Follow-up of Patients with Spinal Muscular Atrophy Treated with OAV101 IT or OAV101 IV in Clinical Trials Novartis Ongoing OAV101 (formerly AVXS-101) 3 COAV101A12308 King Faisal Specialist Hospital and Research Center (Riyadh)
A Phase III, Randomised, Double -Blind, Active-controlled Study to Assess the Efficacy, Safety and Tolerability of Baxdrostat in Combination with Dapagliflozin Compared with Dapagliflozin Alone on Chronic Kidney Disease (CKD) Progression in Participants with CKD and High Blood Pressure AstraZeneca Completed Baxdrostat 3 D6972C00003 King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Specialist Hospital (Dammam),King Khalid University Hospital (Riyadh),King Abdulaziz Medical City NG (Riyadh)
A Phase 3, Open-label, Uncontrolled Study to Evaluate the Activity, Safety, Pharmacokinetics and Pharmacodynamics of Roxadustat for the Treatment of Anemia in Pediatric Participants with Chronic Kidney Disease Astellas Pharma Global Development Inc Ongoing roxadustat 3 1517-CL-1003 King Faisal Specialist Hospital and Research Center (Riyadh)
Brightline-2: A Phase IIa/IIb, open-label, single-arm, multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced / metastatic, MDM2 amplified, TP53 wild-type biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, or other selected solid tumours Boehringer Ingelheim Middle East & North Africa (Scientific Office) FZ Limited Ongoing BI 907828/ brigimadlin 2 1403-0011 King Abdulaziz Medical City NG (Riyadh)
Evaluating the efficacy and safety of Brentuximab Vedotin + AVD (Adriamycin, Vinblastine & Dacarbazine) in Newly Diagnosed Advanced Hodgkin Lymphoma Early Interim PET-Positive Patients; A Multi-Center, Open Label, Single Arm, Phase II, PET-Adaptive Study King Abdullah International Medical Research Center (KAIMRC) Rejected BRENTUXIMAB VEDOTIN 3 RJ19/119/J King Abdulaziz Medical City NG (Riyadh)
Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator’s Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants with Relapsed or Refractory Myeloma who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide Janssen-Cilag International NV Ongoing Talquetamab 3 80202135EBF3001 King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Medical City (Riyadh)
PROSPECTIVE NON-INTERVENTIONAL MULTI-CENTER STUDY EVALUATING BLEEDING INCIDENCE AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH HEMOPHILIA A WITH INHIBITORS AND NON-INHIBITORS TREATED WITH EMICIZUMAB AND OTHER HEMOPHILIA TREATMENTS IN A REAL-LIFE SETTING Roche Ongoing emicizumab 4 MO401001 King Abdulaziz Medical City NG (Jeddah)